DK1106178T3 - Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose - Google Patents

Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose

Info

Publication number
DK1106178T3
DK1106178T3 DK98936715T DK98936715T DK1106178T3 DK 1106178 T3 DK1106178 T3 DK 1106178T3 DK 98936715 T DK98936715 T DK 98936715T DK 98936715 T DK98936715 T DK 98936715T DK 1106178 T3 DK1106178 T3 DK 1106178T3
Authority
DK
Denmark
Prior art keywords
ibudilast
treatment
medicament
manufacture
disseminated sclerosis
Prior art date
Application number
DK98936715T
Other languages
English (en)
Inventor
Saburo Sakoda
Original Assignee
Kyorin Seiyaku Kk
Saburo Sakoda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk, Saburo Sakoda filed Critical Kyorin Seiyaku Kk
Application granted granted Critical
Publication of DK1106178T3 publication Critical patent/DK1106178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
DK98936715T 1998-08-10 1998-08-10 Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose DK1106178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1998/003548 WO2000009127A1 (en) 1998-08-10 1998-08-10 Remedies for multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1106178T3 true DK1106178T3 (da) 2005-02-28

Family

ID=14208769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98936715T DK1106178T3 (da) 1998-08-10 1998-08-10 Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose

Country Status (11)

Country Link
US (1) US6395747B1 (da)
EP (1) EP1106178B1 (da)
JP (1) JP4828003B2 (da)
AT (1) ATE283047T1 (da)
AU (1) AU8562198A (da)
CA (1) CA2339934C (da)
DE (1) DE69827853T2 (da)
DK (1) DK1106178T3 (da)
ES (1) ES2231998T3 (da)
PT (1) PT1106178E (da)
WO (1) WO2000009127A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4589122B2 (ja) * 2002-12-03 2010-12-01 杏林製薬株式会社 ホスホジエステラーゼ１０ａ阻害剤
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
MX2007006777A (es) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
KR100780479B1 (ko) 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
EP2131841B1 (en) * 2007-01-30 2012-08-01 Avigen, Inc. Methods for treating acute pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
PT2187882E (pt) * 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
WO2018119262A1 (en) 2016-12-22 2018-06-28 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
ES2959799T3 (es) * 2018-02-12 2024-02-28 Medicinova Inc Métodos para suprimir células supresoras de origen mieloide en pacientes
WO2019157423A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
CA3135420A1 (en) * 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
CA3115269A1 (en) 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
CN112804999B (zh) 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
US12377074B2 (en) * 2019-06-11 2025-08-05 Yale University Treatment for Wolfram syndrome
US11865214B2 (en) 2019-09-23 2024-01-09 Medicinova, Inc. Ibudilast oral formulations and methods of using same
EP4132521A1 (en) 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
CN116887829A (zh) 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
WO2023049075A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
JP2025504984A (ja) 2022-02-01 2025-02-19 メディシノバ・インコーポレイテッド Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト
CA3261163A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. INJECTABLE FORMULATIONS OF IBUDILAST
WO2026060180A1 (en) 2024-09-11 2026-03-19 Medicinova, Inc. Modified release formulations of ibudilast

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
US6395747B1 (en) 2002-05-28
WO2000009127A1 (en) 2000-02-24
AU8562198A (en) 2000-03-06
CA2339934C (en) 2008-06-03
JP4828003B2 (ja) 2011-11-30
ES2231998T3 (es) 2005-05-16
EP1106178B1 (en) 2004-11-24
EP1106178A4 (en) 2001-11-21
CA2339934A1 (en) 2000-02-24
PT1106178E (pt) 2005-02-28
DE69827853T2 (de) 2005-12-08
DE69827853D1 (de) 2004-12-30
ATE283047T1 (de) 2004-12-15
EP1106178A1 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
PT1106178E (pt) Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DK0594607T3 (da) Forøgelse af nedreguleringen af autoimmune sygdomme ved oral eller enteral indgivelse af autoantigener
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
FR2444671A1 (fr) Nouvelles quinazolinones, leur preparation et medicament contenant ces substances
DK0845984T3 (da) Anvendelse af aminoadamantan-forbindelser som immunregulatorer
ATE360428T1 (de) Analgetisches arzneimittel
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
EP0855397A4 (en) (R) -5-BROMO-N- (1-ETHYL-4-METHYLHEXAHYDRO-1H-1,4-DIAZEPIN-6-YL) -2-METHOXY-6-METHYLAMINO-3-PYRIDINE CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR CONTAINING MEDICAL PREPARATION
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
YU37001A (sh) Kombinacija lekova analgetika
FR2392990A1 (fr) Medicament a base d'un compose heterocyclique bicyclique condense
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
DE3872425D1 (de) Substituierte tetrahydroisochinolin-verbindungen, ihre herstellung und diese enthaltende pharmazeutische mittel.
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью
KR910002818A (ko) 4,5,6,7-사치환된 벤즈옥사졸론
DK1395289T3 (da) Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.